Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand
From Pharmaceutical Executive · · 3 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.